Therefore, the suppression of intermittent hypoxia-induced CCR5 expression or to inhibit the CCR5 function by antagonists could be a reasonable method to avoid the progression of atherosclerosis in OSA patients. The gene discussed is CCR5; the disease is obstructive sleep apnea syndrome.